Tags

Type your tag names separated by a space and hit enter

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Mult Scler. 2018 05; 24(6):811-813.MS

Abstract

BACKGROUND

Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS).

OBJECTIVE

To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male.

METHODS

Case report.

RESULTS

A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course.

CONCLUSION

We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.

Authors+Show Affiliations

Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.Service de Neurologie, Pôle de Neurosciences Cliniques, Hôpital de la Timone, APHM, Marseille, France.Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.Service de Neurologie, Pôle de Neurosciences Cliniques, Hôpital de la Timone, APHM, Marseille, France.Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.Service de Neurologie, Pôle de Neurosciences Cliniques, Hôpital de la Timone, APHM, Marseille, France.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

29359614

Citation

Meunier, Benoit, et al. "Life-threatening Autoimmune Warm Hemolytic Anemia Following Treatment for Multiple Sclerosis With Alemtuzumab." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 24, no. 6, 2018, pp. 811-813.
Meunier B, Rico A, Seguier J, et al. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Mult Scler. 2018;24(6):811-813.
Meunier, B., Rico, A., Seguier, J., Boutiere, C., Ebbo, M., Harle, J. R., Schleinitz, N., & Pelletier, J. (2018). Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Multiple Sclerosis (Houndmills, Basingstoke, England), 24(6), 811-813. https://doi.org/10.1177/1352458517729766
Meunier B, et al. Life-threatening Autoimmune Warm Hemolytic Anemia Following Treatment for Multiple Sclerosis With Alemtuzumab. Mult Scler. 2018;24(6):811-813. PubMed PMID: 29359614.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. AU - Meunier,Benoit, AU - Rico,Audrey, AU - Seguier,Julie, AU - Boutiere,Clemence, AU - Ebbo,Mikael, AU - Harle,Jean Robert, AU - Schleinitz,Nicolas, AU - Pelletier,Jean, Y1 - 2018/01/23/ PY - 2018/1/24/pubmed PY - 2019/9/7/medline PY - 2018/1/24/entrez KW - Multiple sclerosis KW - alemtuzumab KW - hemolytic anemia SP - 811 EP - 813 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 24 IS - 6 N2 - BACKGROUND: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). OBJECTIVE: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. METHODS: Case report. RESULTS: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course. CONCLUSION: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert. SN - 1477-0970 UR - https://www.unboundmedicine.com/medline/citation/29359614/Life_threatening_autoimmune_warm_hemolytic_anemia_following_treatment_for_multiple_sclerosis_with_alemtuzumab_ L2 - https://journals.sagepub.com/doi/10.1177/1352458517729766?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -